Liquidia Corporation LQDA

A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.

Key TakeawaysLiquidia shares are down 14% after BofA cut its price target to $40 from $92, and BTIG and Raymond James both downgraded the stock. The drop follows Wednesday’s roughly 57% crash, after a Delaware court ruled that Yutrepia infringes two claims of a United Therapeutics patent.

Why Liquidia Stock Crashed 57% on Wednesday’s Patent Ruling Against YutrepiaLiquidia (LQDA:NASDAQ) stock crashed 57% on Wednesday, September 30, after a Delaware court ruled that Yutrepia infringes two valid claims of United Therapeutics’ ‘327 patent. Those claims cover treating pulmonary hypertension with interstitial lung disease (PH-ILD) using inhaled treprostinil, and the court struck down the rest.

United Therapeutics Corporation (UTHR:NASDAQ) shares jumped about 13% on Wednesday, September 30 (closing at $542), after a federal court ruled that rival Liquidia’s lung drug infringes its treprostinil patent. Liquidia (LQDA:NASDAQ) fell nearly 50% on the same ruling, wiping out about $3.

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled that competitor Liquidia Corporation infringed patent claims covering United Therapeutics' inhaled treprostinil treatments.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 30, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Stock Market Today: The Dow Jones index rises Wednesday on surprise inflation data. Micron earnings are due after the close.

A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.

Healthcare stocks declined late Wednesday afternoon with the NYSE Healthcare Index and the State Str

Liquidia CEO Roger Jeffs said the company disagrees with the court’s decision and will “pursue all available appellate options.”

Investing.com -- Liquidia Corp shares fell Wednesday after a U.S. District Court in Delaware ruled the company infringed two patent claims held by United Therapeutics Corp. United Therapeutics shares rose more than 13%.

District Court ruled that two of the six claims asserted against Liquidia are valid and infringedParties directed to submit form of judgment, specifying the proposed remedy, for the District Court’s consideration within one week MORRISVILLE, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding